-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $95

Benzinga·12/09/2025 17:17:52
Listen to the news
Morgan Stanley analyst Michael Ulz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price target from $81 to $95.